Whole Genome Sequencing for AML/MDS Risk Stratification
ChromoSeq now covered by Medicare; Two Clinical Trials Also Open Two novel clinical trials for patients diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are open and enrolling patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The clinical trials are utilizing a breakthrough whole-genome […]
Siteman Cancer Center Advances Head and Neck Tumor Discovery
Soon, a global, stage III randomized clinical trial could result in a paradigm shift in how certain head and neck cancers are treated. The clinical trial, called KEYNOTE-689 and overseen by the Merck pharmaceutical company, is the result of specific research initiated by head and neck cancer specialists at Siteman Cancer Center at Barnes-Jewish Hospital […]
Washington University School of Medicine in St. Louis Awarded $10.9 Million SPORE Grant for Pancreas Cancer
New Clinical Trials Set for Pancreatic Ductal Adenocarcinoma Clinical researchers at Washington University School of Medicine in St. Louis have been awarded a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to continue clinical trials and research aimed at advancing pancreatic cancer care. Awarded in July 2023, it marks the […]
Treating Multiple Myeloma — New Immunotherapies
Multiple myeloma has long vexed medical researchers because of the cancer’s specific ability to both weaken and “hide” from a patient’s own immune system. The result is that while many treatments have been able to treat the disease for some time, patients subsequently relapse. But newer medications now can control the disease for extended […]
New Clinical Trials for Prostate, Kidney Cancers
Siteman Cancer Center has three new clinical trials open focused on prostate and kidney cancers. The first, a Phase II clinical trial testing a neoadjuvant immunotherapy treatment for prostate cancer, is available for men who have been diagnosed with localized prostate cancer. The study will evaluate the use of atezolizumab alone and in combination with […]
Early Phase Clinical Trial Focuses on Reducing Tumor Growth and Bone Loss in Patients with Breast Cancer and Bone Metastasis
Beginning next year, Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital will initiate a new early phase clinical trial aimed at stopping bone loss and cancer progression in patients with metastatic breast cancer (MBC). The trial is based on promising laboratory research conducted at the School of Medicine that showed a […]
Washington University to test ‘homegrown’ universal CAR T-cell therapy at Siteman Cancer Center
In early 2022, immunotherapy specialists at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine will begin a new clinical trial using off-the-shelf CAR T-cell therapy for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The therapy, developed by Washington University researchers at Siteman, incorporates many facets of the School […]
Think Clinical Trials after First Diagnosis
Advances in cancer care are happening every day. What’s the best way to find the latest treatment options available for your patients? Check for clinical trials. While many patients think clinical trials are for those who have exhausted all current standard-of-care (SoC) treatments for their type of cancer, the best time to consider participation in […]
First-in-human clinical trials at Siteman Cancer Center to evaluate universal CAR T-cell therapies
This summer, the latest generation of CAR T-cell therapies for patients diagnosed with lymphoma, myeloma or leukemia get underway in clinical trials at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The cancer center was one of the first in the U.S. to offer CAR T-cell therapy for the treatment […]
Newly approved drug effective against lung cancer caused by genetic mutation
The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with […]